PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-14.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-15.16%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
2.78%
Positive EPS growth while GNPX is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
2.78%
Positive diluted EPS growth while GNPX is negative. John Neff might view this as a strong relative advantage in controlling dilution.
19.07%
Share count expansion well above GNPX's 1.54%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
19.07%
Diluted share count expanding well above GNPX's 1.58%. Michael Burry would fear significant dilution to existing owners' stakes.
-16.01%
Dividend reduction while GNPX stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-25.31%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-30.01%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2395.20%
Negative 10Y OCF/share CAGR while GNPX stands at 25.26%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
87.33%
5Y OCF/share CAGR above 1.5x GNPX's 25.26%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
68.32%
Positive 3Y OCF/share CAGR while GNPX is negative. John Neff might see a big short-term edge in operational efficiency.
-1414.90%
Negative 10Y net income/share CAGR while GNPX is at 14.72%. Joel Greenblatt sees a major red flag in long-term profit erosion.
92.17%
5Y net income/share CAGR above 1.5x GNPX's 14.72%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
80.18%
Positive short-term CAGR while GNPX is negative. John Neff would see a clear advantage in near-term profit trajectory.
1411.37%
10Y equity/share CAGR above 1.5x GNPX's 210.08%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-77.60%
Negative 5Y equity/share growth while GNPX is at 210.08%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-28.05%
Negative 3Y equity/share growth while GNPX is at 1989.16%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.41%
Similar asset growth to GNPX's 34.33%. Walter Schloss finds parallel expansions or investment rates.
13.37%
Under 50% of GNPX's 32.52%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-15.85%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
22.47%
R&D dropping or stable vs. GNPX's 71.80%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-1.59%
We cut SG&A while GNPX invests at 104.26%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.